Wall Street Zen Upgrades IQVIA (NYSE:IQV) to Buy

IQVIA (NYSE:IQV) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Friday.

A number of other analysts have also recently weighed in on the stock. JPMorgan Chase & Co. upped their price target on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. TD Cowen cut IQVIA from a “buy” rating to a “hold” rating and upped their price target for the stock from $206.00 to $215.00 in a report on Monday, November 3rd. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. BMO Capital Markets began coverage on IQVIA in a research note on Thursday, November 13th. They set an “outperform” rating and a $260.00 price objective for the company. Finally, Barclays raised their price target on shares of IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $240.61.

IQVIA Stock Performance

NYSE IQV opened at $227.63 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA has a 1-year low of $134.65 and a 1-year high of $234.29. The firm has a market capitalization of $38.77 billion, a P/E ratio of 31.23, a P/E/G ratio of 2.58 and a beta of 1.34. The business’s 50-day simple moving average is $210.07 and its 200-day simple moving average is $183.78.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities analysts predict that IQVIA will post 10.84 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of IQV. Claret Asset Management Corp lifted its stake in IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after purchasing an additional 49 shares during the last quarter. Versant Capital Management Inc grew its position in IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after buying an additional 53 shares during the last quarter. Everpar Advisors LLC increased its holdings in shares of IQVIA by 4.6% in the second quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after buying an additional 62 shares in the last quarter. Private Advisor Group LLC lifted its position in shares of IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares during the last quarter. Finally, Private Trust Co. NA boosted its stake in shares of IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock worth $95,000 after acquiring an additional 67 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.